BioCentury
ARTICLE | Clinical News

NovoNorm repaglinide regulatory update

December 8, 2014 8:00 AM UTC

Japan approved an expanded label for Type II diabetes drug Surepost repaglinide to include combination therapy with oral hypoglycemic agents, excluding sulfonylurea and insulin formulations. Sumitomo ...